VEGFA and neoplasm: Anti-VEGF therapies can counteract these effects: they may reduce Treg and MDSC infiltration, promote DC maturation, and “normalize” the tumor vasculature, potentially facilitating the infiltration and function of effector T cells (Fricke et al., 2007).